Posts

Nxera Pharma Proposes Latest Board Changes with Takeo Morooka Nomination

On February 13, 2026, Nxera Pharma announced Board changes, nominating Mr. Takeo Morooka as new External Director from its Strategic Advisory Council. 2 Ms. Miwa Seki and Mr. Noriaki Nagai will retire from the Board. 2 Appointments subject to approval at the 36th Ordinary General Meeting of Shareholders on March 25, 2026. 2 Mr. Morooka brings expertise in regulatory affairs and pharmaceutical policy from roles like Founder/CEO of PH Consulting and prior Nxera advisory position. 2 Re-appointments include Chris Cargill, David Roblin, Rolf Soderstrom, Naoko Shimura, Nicola Rabson, and Eiko Tomita. 2 Chris Cargill, President & CEO, welcomed Morooka for guidance on growth strategy and thanked outgoing directors. 2 Sources: 2. https://www.globenewswire.com/news-release/2026/02/13/3237936/0/en/Nxera-Pharma-Proposes-Changes-to-its-Board-of-Directors.html

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

HSE Launches Outline Strategic Plan for Laboratory Services 2026-2035

Immunome, Inc. Reports Third Quarter 2025 Financial Results and Business Update

Dianthus Therapeutics Q3 2025 Financial Results and Business Achievements

Rakovina Therapeutics Announces Q3 2025 Financial Results and Corporate Update

Pliant Therapeutics Q3 2025 Financial Results and Corporate Update

Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026

Ultragenyx Announces Layoff of 130 Employees Amid FDA Delays on UX111 Resubmission

Moderna's Outright Flu Refusal Just the Latest Case of Crossed FDA Signals

Dexcom Reports Strong Q4 and Full-Year 2025 Financial Results, Beats Estimates Despite Stock Dip

Immunome, Inc. Reports Q3 2025 Financial Results and Business Update

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2025 Financial Results